Macomics, an immuno-oncology company, secures £3.2 million seed funding from Epidarex Capital & the Scottish Investment Bank

Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, launches today with a £3.2 million seed financing round led by transatlantic VC Epidarex Capital, with the Scottish Investment Bank, the investment arm of Scottish Enterprise, also investing.

  • Facebook
  • Twitter
  • LinkedIn

Ⓒ Copyright Macomics Ltd.
All rights reserved.

  • LinkedIn

Latest News

All the latest developments at Macomics.